Press releasePRNewswire
Protalix Biotherapeutics
PLX · NYSE American
$2.64+$0.08 (+3.13%)TodayMarket closed ·
Prev close $2.56
Latest news
- News
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
- Press releasePRNewswire
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
- Press releasePRNewswire
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
- News
CORRECTION: Protalix BioTherapeutics Q1 EPS $0.22 Beats $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate
- News
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
- News
Earnings Scheduled For May 13, 2026
- Press releasePRNewswire
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
- Press releasePRNewswire
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
Earnings Scheduled For March 18, 2026
- News
Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate
- Press releasePRNewswire
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
- Press releasePRNewswire
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
- Press releaseGlobe Newswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
- Press releaseGlobe Newswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
- Press releaseGlobe Newswire
Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition
- Press releasePRNewswire
Protalix BioTherapeutics Letter to Stockholders
- Press releasePRNewswire
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
- Press releasePRNewswire
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
- News
Preview: Protalix BioTherapeutics's Earnings
- Press releasePRNewswire
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
- Press releaseGlobe Newswire
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releaseBusiness Wire
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
- Press releasePRNewswire
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Press releasePRNewswire
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
- News
Preview: Protalix BioTherapeutics's Earnings
- Press releasePRNewswire
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
- Press releasePRNewswire
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
- Press releasePRNewswire
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
- Press releasePRNewswire
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releasePRNewswire
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
- Press releasePRNewswire
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
- Press releasePRNewswire
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
- News
Earnings Outlook For Protalix BioTherapeutics
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.